Erratum: The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells (International Journal of Oncology (2012) 40 (1483-1491) DOI: 10.3892/ijo.2012.1353);The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1483-1491

  Fujiwara, Jun ^a,b   Sowa, Yoshihiro ^a   Horinaka, Mano ^a   Koyama, Makoto ^a   Wakada, Miki ^a   Miki, Tsuneharu ^b   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Orlistat; Prostate cancer; Reactive oxygen species; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

DEATH RECEPTOR 5; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; UPREGULATION;

EID: 84860265367     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3265     Document Type: Erratum

References (39)

1. Wong WW, Dimitroulakos J, Minden MD and Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16: 508-519, 2002. (Pubitemid 34460459)
2. Kawata S, Yamasaki E and Nagase T, et al: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891, 2001. (Pubitemid 32385829)
3. Sassano A and Platanias LC: Statins in tumor suppression. Cancer Lett 260: 11-19, 2008.
4. Kridel SJ, Axelrod F, Rozenkrantz N and Smith JW: Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64: 2070-2075, 2004. (Pubitemid 38339455)
5. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE and Kuhajda FP: Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56: 2745-2747, 1996. (Pubitemid 26175731)
6. Menendez JA, Vellon L and Lupu R: Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erb B-2) oncogene. Ann Oncol 16: 1253-1267, 2005. (Pubitemid 41166507)
7. Knowles LM, Axelrod F, Browne CD and Smith JW: A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem 279: 30540-30545, 2004. (Pubitemid 38937985)
8. Srivastava RK: TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3: 535-546, 2001.
9. Walczak H, Miller RE and Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999. (Pubitemid 29068521)
10. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H and Okumura K: Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2: 161-169, 2002. (Pubitemid 34461260)
11. Ichikawa K, Liu W and Zhao L, et al: Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7: 954-960, 2001. (Pubitemid 32756434)
12. Koornstra JJ, Kleibeuker JH and van Geelen CM, Rijcken FE, Hollema H, de Vries EG and de Jong S: Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 200: 327-335, 2003. (Pubitemid 36827307)
13. Zhang L and Fang B: Mechanisms of resistance to TRAIL induced apoptosis in cancer. Cancer Gene Ther 12: 228-237, 2005. (Pubitemid 40315182)
14. Ozben T: Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 96: 2181-2196, 2007.
15. Pelicano H, Carney D and Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7: 97-110, 2004. (Pubitemid 38736063)
16. Adler V, Yin Z, Tew KD and Ronai Z: Role of redox potential and reactive oxygen species in stress signaling. Oncogene 18: 6104-6111, 1999.
17. Yoshida T, Maeda A, Tani N and Sakai T: Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett 507: 381-385, 2001. (Pubitemid 33030270)
18. Taniguchi H, Yoshida T and Horinaka M, et al: Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res 68: 8918-8927, 2008.
19. 2 induces apoptosis through activation of the CHOP gene in HeLa cells. Biochem Biophys Res Commun 311: 17-23, 2003.
20. Horinaka M, Yoshida T and Shiraishi T, et al: Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 24: 7180-7189, 2005. (Pubitemid 41679280)
21. Yasuda T, Yoshida T and Goda AE, et al: Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Res 6: 1852-1860, 2008.
22. Yamaguchi H and Wang HG: CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 279: 45495-45502, 2004. (Pubitemid 39491535)
23. Yu R, Mandlekar S, Ruben S, Ni J and Kong AN: Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 60: 2384-2389, 2000. (Pubitemid 30262427)
24. Koksal IT, Sanlioglu AD, Kutlu O and Sanlioglu S: Effects of androgen ablation therapy in TRAIL death ligand and its receptors expression in advanced prostate cancer. Urol Int 84: 445-451, 2010.
25. Horinaka M, Yoshida T and Shiraishi T, et al: The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochem Biophys Res Commun 333: 833-838, 2005. (Pubitemid 40854234)
26. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M and Sakai T: Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23: 6261-6271, 2004. (Pubitemid 39215296)
27. Carracedo A, Gironella M and Lorente M, Garcia S, Guzman M, Velasco G and Iovanna JL: Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 66: 6748-6755, 2006. (Pubitemid 44085633)
28. Senkal CE, Ponnusamy S, Bielawski J, Hannun YA and Ogretmen B: Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J 24: 296-308, 2010.
29. Fu S, Yang L and Li P, et al: Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 473: 528-531, 2011.
30. Yokouchi M, Hiramatsu N and Hayakawa K, et al: Involvement of selective reactive oxygen species upstream of proapoptotic branches of unfolded protein response. J Biol Chem 283: 4252-4260, 2008.
31. Fribley A, Zeng Q and Wang CY: Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24: 9695-9704, 2004. (Pubitemid 39458799)
32. Xue X, Piao JH and Nakajima A, et al: Tumor necrosis factor alpha (TNFα) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFα. J Biol Chem 280: 33917-33925, 2005. (Pubitemid 41443111)
33. 2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription. Mol Cancer Ther 7: 3429-3440, 2008.
34. Lee TJ, Um HJ, Min DS, Park JW, Choi KS and Kwon TK: Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med 46: 1639-1649, 2009.
35. Sung B, Park B, Yadav VR and Aggarwal BB: Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survaival proteins and up-regulation of death receptors. J Biol Chem 285: 11498-11507, 2010.
36. Sung B, Ravindran J, Prasad S, Pandey MK and Aggarwal BB: Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem 285: 35418-35427, 2010.
37. Prasad S, Yadav VR, Ravindran J and Aggarwal BB: ROS and CHOP are critical for dibenxylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins. Cancer Res 71: 538-549, 2011.
38. Yang JF, Cao JG, Tian L and Liu F: 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells. Cancer Chemother Pharmacol: Jun 10, 2011 (Epub ahead of print).
39. Yadav VR, Prasad S and Aggrwal BB: Cardomonin sensitizes tumor cells to TRAIL through ROS- and CHOP-mediated upregulation of death receptors and downregulation of survival proteins. Br J Pharmacol: Jul 28, 2011 (Epub ahead of print). doi: 10.1111/j.1476-5381.2011.01603.x.